港股异动 | 中芯国际涨3.3% 股价创去年6月以来新高
格隆汇9月18日丨中芯国际(0981.HK)涨3.3%,报10.64港元,股价创去年6月以来新高,成交3.3亿港元,H股总市值538亿港元。公司是世界领先的集成电路晶圆代工企业之一,2019第二季度在晶圆代工厂中排名第五,同时也是中国内地技术最先进、配套最完善、规模最大、跨国经营的IC制造企业。天风证券近日发布研报称,看好5G、AIoT及国产替代等对公司的长期驱动,维持公司2019年EPS为0.17港币的预期,预计2020-2021年EPS分别为0.22、0.43港币。预计随着14/12nm的量产,ROE回升,给予公司1.6倍PB,对应目标价13.84港币。将评级从“增持”调高到“买入”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.